Bravecto kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (black-legged tick) infestations for 12 weeks in cats and kittens 6 months of age and older, and weighing 2.6 pounds or greater.
Bravecto is also indicated for the treatment and control of Dermacentor variabilis (American dog tick) infestations for 8 weeks in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.
For topical use only. Avoid oral ingestion. Bravecto has not been shown to be effective for 12-weeks duration in kittens less than 6 months of age. The safety of Bravecto has not been established in breeding, pregnant and lactating cats.
Bravecto should be administered topically as a single dose every 12 weeks according to the Dosage Schedule below to provide a minimum dose of 18.2 mg/lb (40 mg/kg) body weight.
Bravecto may be administered every 8 weeks in case of potential exposure to Dermacentor variabilis ticks
Bravecto may be administered every 8 weeks in case of potential exposure to Dermacentor variabilis ticks.
|Body Weight Ranges (Lb)||Fluralaner content (mg/tube)||Tubes Administered|
|2.6 - 6.2||112.5||One|
|>6.2 - 13.8||250||One|
|>13.8 - 27.5||500||One|